GMP IPO Watch
DSP Healthcare Fund
Direct Plan · Growth · DSP Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | -3.06% | -1.28% | 239 of 255 |
| 1M | -3.45% | -4.58% | 62 of 253 |
| 3M | +3.21% | -2.57% | 33 of 251 |
| 6M | +23.07% | +11.42% | 35 of 251 |
| YTD | +14.38% | -0.16% | 72 of 255 |
| 1Y | +15.62% | +2.02% | 74 of 228 |
| 2Y | +5.78% | -0.19% | 126 of 183 |
| 3Y | +20.65% | +11.77% | 86 of 141 |
| 5Y | +15.23% | +9.69% | 87 of 102 |
| 7Y | +25.89% | +14.91% | 44 of 83 |
| INCEPTION | +22.68% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +5.98% | +44.87% | -16.09% | 71% | 29% |
| 6M | +12.12% | +78.03% | -17.75% | 74% | 31% |
| 1Y | +26.95% | +97.11% | -14.02% | 81% | 38% |
| 2Y | +26.01% | +57.84% | +3.05% | 100% | 47% |
| 3Y | +23.72% | +35.13% | +14.96% | 100% | 49% |
| 5Y | +24.09% | +35.56% | +14.25% | 100% | 48% |
| 7Y | +23.92% | +26.67% | +21.10% | 100% | 49% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Aug 2026
Asset Allocation
- Equity96.14%
- Debt0.00%
- Cash2.88%
- Other0.98%
Market Cap Split
- Large Cap25.92%
- Mid Cap13.81%
- Small Cap44.47%
- Others15.80%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 37.17 | 42.86 |
| P/B | 5.01 | 6.43 |
| Price / Sales | 5.12 | 6.30 |
| Price / Cash Flow | 28.98 | 32.07 |
| Dividend Yield (%) | 0.61 | 0.59 |
Holdings · Aug 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 8.74% | +0.57% |
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 7.95% | -0.47% |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 7.45% | +0.35% |
| Cipla | Pharmaceuticals & Biotechnology | 7.35% | -0.78% |
| Apollo Hospitals | Equity | 6.47% | +0.66% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 5.98% | -0.37% |
| Globus Medical Inc | Equity | 5.44% | -0.13% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 4.15% | +1.81% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 4.08% | -0.58% |
| Cohance Lifesciences | Pharmaceuticals & Biotechnology | 3.81% | +0.06% |
| TREPS / Reverse Repo Investments | Reverse Repo / TREPS | 3.77% | — |
| Manipal Health Enterprises | Equity | 3.70% | +0.68% |
| Pfizer | Pharmaceuticals & Biotechnology | 3.22% | +0.49% |
| Alembic Pharmaceuticals | Pharmaceuticals & Biotechnology | 3.14% | -0.03% |
| Kovai Medical Center Hospital | Equity | 2.80% | +0.06% |
View all 33 holdings
| Concord Biotech | Pharmaceuticals & Biotechnology | 2.77% | +0.82% |
| Vijaya Diagnostic Centre | Equity | 2.44% | -1.03% |
| Procter & Gamble Health | Pharmaceuticals & Biotechnology | 2.40% | -0.50% |
| Thyrocare Technologies | Equity | 2.11% | — |
| Indoco Remedies | Pharmaceuticals & Biotechnology | 2.06% | +0.10% |
| Intuitive Surgical Inc | Equity | 1.76% | +0.02% |
| Unichem Laboratories | Pharmaceuticals & Biotechnology | 1.64% | +0.05% |
| Syngene International | Equity | 1.31% | -0.02% |
| Nephrocare Health Services | Equity | 1.13% | -0.06% |
| ICICI Lombard General Insurance | Insurance | 0.99% | -0.09% |
| Global X Funds - Global X Genomics & Biotechnology ETF | Foreign Security | 0.98% | +0.11% |
| Aarti Drugs | Pharmaceuticals & Biotechnology | 0.91% | -0.08% |
| Abbott Laboratories | Pharmaceuticals & Biotechnology | 0.87% | -0.01% |
| Eris Lifesciences | Pharmaceuticals & Biotechnology | 0.76% | -0.08% |
| Jupiter Life Line Hospital | Equity | 0.40% | -0.07% |
| Grail Inc | Equity | 0.17% | +0.01% |
| Laxmi Dental | Equity | 0.14% | -0.02% |
| Net Receivables/Payables | Net Current Assets | -0.89% | — |
Sector Allocation · Aug 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 12.96 | 14.22 | Low Volatility |
| 3Y | 15.19 | 16.08 | Low Volatility |
| 5Y | 15.05 | 15.48 | Low Volatility |
What is this?
Risk as measured by standard deviation is a statistical measure that quantifies the amount of variation or dispersion in a set of data points relative to its mean (average).
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.79 | 1.00 | Poor Risk Adjusted Returns |
| 3Y | 0.93 | 0.94 | Poor Risk Adjusted Returns |
| 5Y | 0.65 | 0.58 | Good Risk Adjusted Returns |
What is this?
Higher the value means that fund has been able to give better returns for the amount of risk taken. It helps investors understand the return of an investment compared to its risk, showing whether the returns are due to intelligent investing or simply taking on excess risk. It is calculated by subtracting the risk-free return, defined as an Indian Government Bond, from the fund's returns, and then dividing by the standard deviation of returns.
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.33 | 1.82 | Poor Risk Adjusted Returns |
| 3Y | 1.65 | 1.63 | Good Risk Adjusted Returns |
| 5Y | 1.07 | 0.94 | Good Risk Adjusted Returns |
What is this?
The Sortino Ratio is a financial metric used to measure the risk-adjusted return of an investment. It's a modification of the Sharpe Ratio but with a key difference; it only considers downside risk (the risk of negative returns), rather than total volatility. This means it focuses on how well an investment performs relative to the volatility that leads to losses, ignoring the volatility that results in gains. The idea is that investors are primarily concerned with minimizing losses, and positive volatility is generally seen as a good thing.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.90 | 0.94 | Good Risk Adjusted Returns |
| 3Y | 0.85 | 0.95 | Good Risk Adjusted Returns |
| 5Y | 0.88 | 0.94 | Good Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+125.07% | +61.55% | — | +32.55% |
|
Franklin Asian Equity Fund
Regular Plan · IDCW
|
+31.28% | +22.70% | +6.52% | +4.42% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+28.99% | +22.97% | +10.76% | +9.17% |
|
Motilal Oswal Active Momentum Fund
Direct Plan · Growth
|
+26.04% | — | — | +27.23% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+25.57% | +29.81% | — | +29.73% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+25.46% | — | — | +19.77% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+24.20% | — | — | +11.25% |
|
Motilal Oswal Special Opportunities Fund
Direct Plan · Growth
|
+19.68% | — | — | +19.59% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+19.63% | — | — | +8.42% |
|
Edelweiss Recently Listed IPO Fund
Regular Plan · Growth
|
+19.17% | +15.58% | +9.91% | +14.76% |
More From DSP Asset Managers Private Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
| DSP Silver ETF | +52.35% | +47.45% | — | +38.32% |
|
DSP Silver ETF Fund of Fund
Direct Plan · IDCW
|
+50.75% | — | — | +81.98% |
|
DSP World Mining Overseas Equity Omni FoF
Direct Plan · Growth
|
+39.49% | +28.39% | +20.72% | +8.86% |
|
DSP US Specific Equity Omni FoF
Direct Plan · Growth
|
+31.45% | +28.56% | +19.67% | +17.96% |
|
DSP World Gold Mining Overseas Equity Omni FoF
Direct Plan · IDCW
|
+28.44% | +51.43% | +25.17% | +6.88% |
| DSP Gold ETF | +25.47% | +36.24% | — | +28.71% |
|
DSP Gold ETF Fund of Fund
Direct Plan · IDCW
|
+25.12% | — | — | +34.07% |
|
DSP Global Innovation Overseas Equity Omni FoF
Direct Plan · Growth
|
+24.14% | +29.95% | — | +20.17% |
|
DSP Global Clean Energy Overseas Equity Omni FoF
Direct Plan · Growth
|
+23.17% | +19.51% | +10.68% | +6.87% |
|
DSP Small Cap Fund
Direct Plan · Growth
|
+16.51% | +16.79% | +16.84% | +21.23% |
About This Scheme
Investment Objective
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies/entities. There is no assurance that the investment objective of the Scheme will be achieved.
Stated Asset Allocation
1.Equity and Equity related Instruments of Pharmaceutical and Healthcare companies / entities: 80% - 100% 2. Other Equity and Equity related Instruments/ Money Market Instruments / InvITs/ Gold ETFs / Silver ETFs / Other Liquid Instruments / Units of Domestic Mutual Funds^: 0% - 20% For detailed asset allocation pattern, please refer to the Scheme Information Document^Any other security as may be permitted by SEBI/ RBI from time to time. Other Liquid instruments includes cash, bank deposits with Scheduled Commercial Banks, Government Securities, Treasury bills, Repo on Government securities and any other instruments as specified by the SEBI. The scheme may invest in the units of Overnight Fund, Money Market Fund & Liquid Fund (including Liquid ETFs) of Domestic Mutual Fund.
Exit Load
0.50% - Holding period from the date of allotment <= 1 month, Nil - Holding period from the date of allotment > 1 month (as a % of Applicable NAV)
Fund Managers
Mr. Chirag Dagli
Mr. Chirag Dagli - Primary (Equity and Overseas portion)
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.